Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

MediciNova announces start of MN-166 clinical study for marijuana dependence

March 11, 2014

Titan Pharmaceuticals and FDA discuss path forward for Probuphine

March 4, 2014

Humanetics and USAMRICD enter into CRADA to study BIO-300 to treat phosgene exposure

Feb. 26, 2014

FDA clears path for smoking cessation trial of INV-102

Jan. 30, 2014

Phase I study of novel treatment candidate for alcoholism begins patient recruitment

Jan. 27, 2014

FDA grants orphan drug status to Aeolus' drug candidate for treatment of acute radiation syndrome

Jan. 24, 2014

Neumedicines' HemaMax shown to improve survival outcomes following lethal irradiation

Jan. 10, 2014

Neumedicines joins the Alliance for Biosecurity

Jan. 7, 2014

Takeda submits NDA for fomepizole in Japan

Dec. 30, 2013

Pharmacological data presented for a selective nAChR desensitizer

Dec. 11, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...